Related Experiment Video
Updated: Jul 20, 2025
Production of Recombinant PRMT Proteins using the Baculovirus Expression Vector System
Published on: July 17, 2021
Application of Baculovirus Expression Vector System (BEVS) in Vaccine Development.
Qiaonan Hong1, Jian Liu1, Yuquan Wei1
1Department of Biotherapy, Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 610041, China.
The baculovirus expression vector system (BEVS) offers a flexible, rapid, and cost-effective platform for vaccine production. This review explores BEVS development and its potential for future vaccine manufacturing and epidemic control.
Area of Science:
- Biotechnology
- Vaccinology
- Molecular Biology
Background:
- Vaccination is crucial for epidemic control, driving demand for efficient vaccine production platforms.
- Existing methods face challenges in flexibility, speed, and cost-effectiveness.
- The baculovirus expression vector system (BEVS) presents a promising alternative.
Purpose of the Study:
- To review the development and application of BEVS in vaccine production.
- To summarize the advantages and limitations of the BEVS platform.
- To explore future prospects of BEVS in vaccine manufacturing.
Main Methods:
- Literature review of BEVS development history.
- Analysis of recombinant protein vaccine preparation using BEVS.
- Summary of BEVS features, limitations, and progress in vaccine research.
Main Results:
- BEVS demonstrates high safety, rapid production, flexible design, and scalability for vaccines.
- Significant progress has been made in BEVS-related vaccine research.
- BEVS technology is adaptable for various vaccine types.
Conclusions:
- BEVS is a viable and advantageous platform for producing recombinant protein vaccines.
- Further development of BEVS holds significant promise for future vaccine manufacturing.
- BEVS can contribute to addressing global health challenges through efficient vaccine production.
